BCLI - ブレインスト―ム・セル・セラピュ―ティクス (Brainstorm Cell Therapeutics Inc.) ブレインスト―ム・セル・セラピュ―ティクス



symbol BCLI
会社名 Brainstorm Cell Therapeutics Inc (ブレインスト―ム・セル・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS also known as Lou Gehrig's disease) Multiple Sclerosis (MS) and Parkinson's disease (PD) among others. Its subsidiary Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary) holds rights to commercialize the technology NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.   ブレインスト―ム・セル・セラピュ―ティクスは、米国のバイオテクノロジ―会社。筋萎縮性側索硬化症(ル―・ゲ―リック病としても知られている)、多発性硬化症、およびパ―キンソン病などの神経変性疾患を衰弱させるための成体幹細胞治療を開発する。「NurOwn」は、同社独自のプロセスで、神経変性疾患を治療するために設計されている。   BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm is also conducting an FDA-approved Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed dosing in December 2020, and topline results are expected by the end of the first quarter 2021.
本社所在地 1325 Avenue of Americas 28th Floor New York NY 10019 USA
代表者氏名 Irit Arbel Irit Arbel
代表者役職名 Independent Chairman of the Board
電話番号 +1 201-488-0460
設立年月日 36770
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 24人
url www.brainstorm-cell.com
nasdaq_url https://www.nasdaq.com/symbol/bcli
EBITDA EBITDA(百万ドル) -7.44100
終値(lastsale) 3.62
時価総額(marketcap) 74823691.36
時価総額 時価総額(百万ドル) 75.44378
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 58.00478
当期純利益 当期純利益(百万ドル) -7.51600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Brainstorm Cell Therapeutics Inc revenues was not reported. Net loss increased 91% to $5.4M. Higher net loss reflects General and administrative - Balancing v increase of 93% to $2.6M (expense) Research and development - Balancing val increase of 85% to $2.4M (expense) Stock-based Compensation in SGA increase from $108K to $315K (expense).



   Is Brainstorm Cell Therapeutics Inc. (BCLI) A Good Stock To Buy?  2021/06/22 23:17:14 Insider Monkey
   Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets  2021/06/15 13:21:00 Business Insider Markets
NEW YORK, June 15, 2021 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents and patent
   Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS  2021/05/30 17:05:25 Seeking Alpha
   Global Gene and Cell Therapies Targeting CNS Disorders Market 2021-2026 Featuring Emerging Drugs - NurOwn (BrainStorm Cell Therapeutics) & Neuro-Cells (Neuroplast)  2021/05/26 10:18:00 GlobeNewswire
Dublin, May 26, 2021 (GLOBE NEWSWIRE) -- The "Gene and Cell Therapies Targeting CNS Disorders - Market Insights and Market Forecast - 2026" report has been added to ResearchAndMarkets.com''s offering.
   BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting  2021/05/25 20:21:00 Finanzen AT
NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF
   Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS  2021/05/30 17:05:25 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ブレインスト―ム・セル・セラピュ―ティクス BCLI Brainstorm Cell Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)